Trial Profile
An open-label, prospective pilot study evaluating the effect of adalimumab on endothelial function and on cardiovascular biomarkers in severe chronic plaque psoriasis patients eligible for biologic treatment in Australia
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Jun 2016
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Biomarker; Pharmacodynamics
- 28 May 2013 New trial record